🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge
Demo corpus. Scores are computed on a select set of biomedical paper/datasets and may be inaccurate for papers outside this corpus — DataRank relies on network effects that improve with scale. We aim to expand this into a fully open resource pending additional funding.

Hallmarks of Cancer: New Dimensions

Cancer Discovery(2022)10.1158/2159-8290.cd-21-1059Source: DataRank Database

Hallmarks of Cancer: New Dimensions is a research paper published in Cancer Discovery (2022). On theSindex it has a DataRank of 1.4. It has been cited 8,791 times.

N/A
1.4DataRank · unranked
1.4
Open Access8791 citations · base score 9.1
Cite:
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Abstract

The hallmarks of cancer conceptualization is a heuristic tool for distilling the vast complexity of cancer phenotypes and genotypes into a provisional set of underlying principles. As knowledge of cancer mechanisms has progressed, other facets of the disease have emerged as potential refinements. Herein, the prospect is raised that phenotypic plasticity and disrupted differentiation is a discrete hallmark capability, and that nonmutational epigenetic reprogramming and polymorphic microbiomes both constitute distinctive enabling characteristics that facilitate the acquisition of hallmark capabilities. Additionally, senescent cells, of varying origins, may be added to the roster of functionally important cell types in the tumor microenvironment. SIGNIFICANCE: Cancer is daunting in the breadth and scope of its diversity, spanning genetics, cell and tissue biology, pathology, and response to therapy. Ever more powerful experimental and computational tools and technologies are providing an avalanche of "big data" about the myriad manifestations of the diseases that cancer encompasses. The integrative concept embodied in the hallmarks of cancer is helping to distill this complexity into an increasingly logical science, and the provisional new dimensions presented in this perspective may add value to that endeavor, to more fully understand mechanisms of cancer development and malignant progression, and apply that knowledge to cancer medicine.

Data sources & pipeline
Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring
Enrichment:Pending

FAIR Checklist

Context only (not used in score)
Findable (1/2)
  • Has DOI
Accessible (1/2)
  • Open Access
Interoperable (0/2)
    Reusable (0/3)

      FAIR checklist signals are shown for context only and do not affect DataRank scoring.

      DataRank Breakdown

      Base Score 100%Citation Network 0%

      Base Score Contribution

      1.4

      From this paper's citation signal

      Citation Network Contribution

      0

      Citation network not refreshed for this result

      This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

      Learn more about DataRank methodology →
      Why this DataRank?

      DataRank blends this paper's own citation count with the influence of the papers that cite it. Here, roughly 100% comes from its base citations and 0% from the citation network.

      Base score B(p)
      log1p(citation_count) — grows sub-linearly, so a paper with 1,000 citations is not 10× a paper with 100.
      Network N(p)
      Σ over citers of log1p(Cq) ÷ max(outdegreeq, 1). Being cited by a highly-cited paper with few references counts most.
      Damping factor d = 0.85
      DataRank = (1−d)·B(p) + d·N(p) — the two cards above are each already multiplied by their share.
      Self-citations excluded
      Citers sharing any OpenAlex author ID with this paper are filtered out before the network sum.

      Citers are pulled from OpenAlex sorted by cited_by_count:descand capped per paper, so when the cap binds we keep the highest-signal references and the score is reproducible across reruns.

      Read the full methodology →

      Authors (1)